{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"28.8","upperLimit":"40.6","value":"34.7"},{"groupId":"OG001","lowerLimit":"31.7","upperLimit":"42.9","value":"37.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"248"},{"groupId":"OG001","value":"284"}],"units":"Participants"}],"description":"Pain response was defined as either a ≥2-point decrease from baseline median PPI score without increase in AS, or a ≥50% decrease from baseline mean AS without increase in the PPI score, maintained for 2 consecutive evaluations at least 3 weeks apart. Increases in pain during the first 12 weeks were ignored in determining pain response.","dispersionType":"95% Confidence Interval","groups":[{"description":"Cabazitaxel 20 mg/m\\^2 IV infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until DP, unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles.","id":"OG000","title":"Cabazitaxel 20 mg/m^2"},{"description":"Cabazitaxel 25 mg/m\\^2 IV infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until DP, unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles.","id":"OG001","title":"Cabazitaxel 25 mg/m^2"}],"paramType":"NUMBER","populationDescription":"Analysis was performed on ITT population. Number of participants analyzed= participants evaluable for pain response with pain score with median PPI ≥2 and/or mean AS ≥10 points at baseline and at least one valid post-baseline value.","reportingStatus":"POSTED","timeFrame":"From baseline until DP, start of another anti-cancer therapy, death or study cut-off date (maximum duration: 48 months)","title":"Percentage of Participants With Pain Response","type":"SECONDARY","unitOfMeasure":"percentage of participants"}